Purpose To evaluate the prognostic value of minimal residual disease (MRD) in patients
with acute myeloid leukemia (AML) with NPM1 mutation (NPM1 mut). Patients and Method …

FOXM1 is a transcription factor of the Forkhead family that is required for cell proliferation of
normal cells. However, FOXM1 is repeatedly overexpressed in a variety of human cancers …

Purpose To study the incidence and prognostic impact of mutations in DNA
methyltransferase 3A (DNMT3A) in patients with acute myeloid leukemia. Patients and …

Although the majority of patients with acute myeloid leukemia (AML) treated with intensive
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …

Purpose Risk stratification in acute myeloid leukemia (AML) is currently based on
pretreatment characteristics. It remains to be established whether relapse risk can be better …

Although improvement in outcomes has occurred in younger adults with acute myeloid
leukemia (AML) during the past 4 decades, progress in older adults has been much less …

The chromatin reader eleven–nineteen leukemia (ENL) has been identified as a critical
dependency in acute myeloid leukemia (AML), but its therapeutic potential remains unclear …

Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have
been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of …

Nucleophosmin (NPM1) exon-12 gene mutations are the hallmark of a large acute
myelogenous leukemia (AML) subgroup with normal karyotype, but their prognostic value in …

Mutations in nucleophosmin NPM1 are the most frequent acquired molecular abnormalities
in acute myeloid leukemia (AML). We determined the NPM1 mutation status in a clinically …